The elevated P/S multiple reflects a market expectation of future breakthrough success in neurostimulation rather than a reflection of current operational health. Given the lack of positive earnings or EBITDA, traditional valuation metrics are largely inapplicable, forcing investors to rely on the probability of regulatory milestones being met.

The persistent negative returns on capital are a direct consequence of the company's heavy R&D expenditure relative to its minimal revenue base. This trend suggests that until the company can transition from a clinical-stage entity to a commercial-scale provider, capital efficiency will remain severely constrained by fixed costs.

The erratic nature of the cash conversion cycle is likely driven by the lumpy, project-based revenue recognition typical of licensing agreements. This lack of operational consistency makes it difficult for management to forecast cash needs, further exacerbating the risks associated with the company's already thin liquidity position.

The liquidity position appears precarious, as the company remains entirely dependent on external capital to bridge the gap between its current cash reserves and its significant operating losses. Investors should monitor the potential for further dilutive equity raises, which appear necessary to sustain operations in the near term.